ArticleCancer science2012
Therapeutic upregulation of Class A scavenger receptor member 5 inhibits tumor growth and metastasis.
Article in Cancer science, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 56 citations in OpenAlex.
- Genome-wide association study of urinary cadmium levels in current smokers from the multiethnic cohort study.Human molecular genetics · 2025Article
- The Role of SCARA5 as a Potential Biomarker in Squamous Cell Carcinoma of the Lung.International journal of molecular sciences · 2024Article
- SCARA5 Is Overexpressed in Prostate Cancer and Linked to Poor Prognosis.Diagnostics (Basel, Switzerland) · 2023Article
- Decreased expression ofFrontiers in oncology · 2023Article
- SCARA5 inhibits oral squamous cell carcinoma via inactivating the STAT3 and PI3K/AKT signaling pathways.Open medicine (Warsaw, Poland) · 2023Article
- Carcinoma-associated fibroblasts release microRNA-331-3p containing extracellular vesicles to exacerbate the development of pancreatic cancerCancer biology & therapy · 2022Article
- SCARA5 induced ferroptosis to effect ESCC proliferation and metastasis by combining with Ferritin light chain.BMC cancer · 2022Article
- Potential of Ferritin-Based Platforms for Tumor Immunotherapy.Molecules (Basel, Switzerland) · 2022Review
- Fusion of Normoxic- and Hypoxic-Preconditioned Myoblasts Leads to Increased Hypertrophy.Cells · 2022Article
- Scavenger receptors in host defense: from functional aspects to mode of action.Cell communication and signaling : CCS · 2022Review
- Computational Analysis of the Immune Infiltration Pattern and Candidate Diagnostic Biomarkers in Lumbar Disc Herniation.Frontiers in molecular neuroscience · 2022Article
- PepFect14 Signaling and Transfection.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Highly ExpressingJournal of immunology research · 2022Article
- Tumor suppressive effect of scavenger receptor class A member 5 overexpression in colorectal cancer by regulating PI3K/AKT/mTOR pathway.Genes & genomics · 2021Article
- SCARA5 suppresses the proliferation and migration, and promotes the apoptosis of human retinoblastoma cells by inhibiting the PI3K/AKT pathway.Molecular medicine reports · 2021Article
- SCARA5 inhibits gastric cancer progression via epithelial-mesenchymal transition suppression.Journal of Cancer · 2021Article
- SCARA5 plays a critical role in the commitment of mesenchymal stem cells to adipogenesis.Scientific reports · 2017Article
- SCARA5 plays a critical role in the progression and metastasis of breast cancer by inactivating the ERK1/2, STAT3, and AKT signaling pathways.Molecular and cellular biochemistry · 2017Article
- Methylation analysis of p16, SLIT2, SCARA5, and Runx3 genes in hepatocellular carcinoma.Medicine · 2017Article
- Transcriptional landscape of human cancers.Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Class A scavenger receptor member 5 (SCARA5) is a new member of the Class A scavenger receptors that has been proposed recently as a novel candidate tumor suppressor gene in human hepatocellular carcinoma. In the present study, we found that SCARA5 expression was frequently downregulated in various cancer cell lines and tumor samples. In addition, upregulation of SCARA5 expression in human cancer cell line (U251) led to a significant decrease in cell proliferation, clone formation, migration, and invasion in vitro. Furthermore, systemic treatment of tumor-bearing mice with SCARA5-cationic liposome complex not only reduced the growth of subcutaneous human glioma tumors, but also markedly suppressed the spontaneous formation of lung metastases. Similar results were obtained in another experiment using mice bearing experimental A549 lung metastases. Compared with the untreated control group, mice treated with SCARA5 exhibited reductions in both spontaneous U251 and experimental A549 lung metastases rates of 77.3% and 70.2%, respectively. Western blot analysis was used to explore the molecular mechanisms involved and revealed that SCARA5 physically associated with focal adhesion kinase. Interestingly, upregulation of SCARA5 inactivated signal transducer and activator of transcription 3, as well as downstream signaling including cyclinB1, cyclinD1, AKT, survivin, matrix metalloproteinase-9 and vascular endothelial growth factor-A. Overall, the findings of the present study provide the first evidence that SCARA5 might be a promising target for the development of new antimetastatic agents for the gene therapy of cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.